Loading
Brand names: Various • Drug class: Insulin
Insulin requirements FALL as kidney function declines — the kidney clears insulin, so CKD prolongs its action. Insulin doses often need reduction in advanced CKD and dialysis, with hypoglycemia the main danger. For diabetic kidney disease, insulin is the reliable fallback when oral agents are limited.
The kidney degrades about 30-50% of circulating insulin. As GFR falls, insulin half-life lengthens — the same dose can cause hypoglycemia. Dialysis improves insulin clearance somewhat, and dosing windows (before vs after sessions) need coordination with meals and dialysis timing. Metformin and SGLT2i are preferred earlier in CKD; insulin becomes increasingly central as GFR falls.
Renal insulin clearance decreases with declining GFR — doses often need reduction in advanced CKD
Diabetic kidney disease pharmacology literature, 2023
Hypoglycemia risk rises in CKD; conservative titration and glucose monitoring advised
Guideline consensus, 2022
No fixed formula — titrate to glucose targets with close monitoring. Expect dose reductions as eGFR falls below ~30-45; coordinate with dialysis sessions (in-center patients often take less on dialysis days). Use glucose self-monitoring (or CGM where available) and conservative titration.
Check your kidney functionThis page is educational. Medication decisions — especially dosing changes — must be made by your prescribing clinician.
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and obesity. The FLOW trial (NEJM 2024) showe…
Learn moreSGLT2 inhibitors — originally diabetes drugs — are now a cornerstone of kidney disease treatment. DAPA-CKD and…
Learn moreDapagliflozin is the first SGLT2 inhibitor proven to protect kidneys in CKD with and without diabetes (DAPA-CK…
Learn moreEmpagliflozin is an SGLT2 inhibitor approved for CKD with albuminuria (eGFR ≥20) and heart failure. The EMPA-K…
Learn more